Why the study?
Little is known about the pharmacodynamic effect of syringaresinol on modulating diabetic cardiomyopathy and its underlying molecular mechanism.
Does syringaresinol improve cardiac dysfunction and fibrosis in models of type 1 diabetic cardiomyopathy?
Population
STZ-induced type 1 diabetic mice and neonatal cardiomyocytes
Comparison
Oral syringaresinol vs control in vivo, and syringaresinol incubation vs high glucose in vitro
Design
In vivo and in vitro animal and cell study
Follow-up
8 weeks
Authors
Loading...
SYR attenuates diabetic cardiomyopathy in mice; hypothesis-generating and leaves open human translation.
Does syringaresinol improve cardiac dysfunction and fibrosis in models of type 1 diabetic cardiomyopathy?
Syringaresinol demonstrates protective effects against type 1 diabetic cardiomyopathy in preclinical models by modulating Keap1/Nrf2 and TGF-β/Smad signaling pathways.
Yang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: